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aclitaxel-Eluting Stents in Daily Practice
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OBJECTIVES We compared the clinical outcome of sirolimus-eluting stents (SES) and paclitaxel-eluting
stents (PES) in a real-world scenario.
BACKGROUND In selected patients, SES has been associated with lower late luminal loss than PES. Whether
this emerging biological difference could translate into different clinical efficacy in daily
practice is presently unknown.
METHODS This analysis included 1,676 consecutive patients with de novo coronary lesions treated solely
with drug-eluting stents (SES  992; PES  684). All patients were enrolled in a dynamic
prospective registry comprising 13 hospitals. We assessed the cumulative incidence of major
adverse cardiac events (MACE), defined as death, myocardial infarction (MI), and target
vessel revascularization (TVR) during follow-up.
RESULTS Overall, 29% of the patients had diabetes, 23% had prior MI, and 9% had poor left ventricular
function. ST-segment elevation MI was diagnosed at admission in 12%. Multivessel
intervention was performed in 16%. At 1-year follow-up, SES was associated with a reduced
incidence of MACE (9.2% SES vs. 14.1% PES; p  0.007) and TVR (5.0% SES vs. 10.0%
PES; p  0.0008) compared to PES. A propensity analysis with many clinical and
angiographic variables was carried out to adjust for baseline differences. In this analysis, SES
was associated with a 44% risk reduction of MACE (hazard ratio 0.56, 95% confidence
interval 0.39 to 0.78) and a 55% reduction of TVR (hazard ratio 0.45, 95% confidence interval
0.29 to 0.70). This result was consistent across most subgroups tested. Similar rates of death
and MI were observed in the 2 treatment groups.
CONCLUSIONS In this large real-world population, SES improved 1-year clinical results as compared to
PES. (J Am Coll Cardiol 2006;48:1312–8) © 2006 by the American College of Cardiology
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.063Foundation
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Snumber of clinical trials have demonstrated a clear superi-
rity of the sirolimus-eluting stent (SES) and polymer-
oated paclitaxel-eluting stent (PES) over a bare metal stent
or the prevention of restenosis and the need for further
evascularization (1–5). In head-to-head comparisons, SES
as been consistently associated with lower in-stent late
uminal loss than PES (6–9). However, the importance of
his angiographic end point as a surrogate of clinical events
as been questioned.
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ccepted March 28, 2006.Indeed, the interrelationship among angiographic late
oss, binary restenosis, and clinical recurrence after coronary
tent implantation has been incompletely evaluated, and this
olds especially true in the drug-eluting stent era. However,
lthough small differences in luminal late loss did not seem
o be important in the setting of nearly ideal patients and
esions treated in randomized trials, they might be pivotal in
ore complex patients and lesions as treated in the real
orld. Accordingly, SES has been associated with a clinical
dvantage over PES only in trials enrolling patients at high
isk of restenosis.
The present study was therefore conducted to compare the
-year clinical outcome of patients treated with SES and PES
n a large multicenter registry comprising patients with a broad
ariety of clinical characteristics and lesion characteristics.
ETHODS
tudy design and patient population. The REAL registry
REgistro regionale AngiopLastiche dell’Emilia-Romagna)
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October 3, 2006:1312–8 Sirolimus- Versus Paclitaxel-Eluting Stentsas been previously described (10). Briefly, the REAL is a
arge prospective web-based registry launched in July 2002
nd designed to collect clinical and angiographic data of all
onsecutive percutaneous coronary interventions (PCIs)
erformed in a 4-million-resident Italian region. Thirteen
ublic and private centers of interventional cardiology par-
icipate in data collection. The present study focuses on all
atients who were treated exclusively with the Cypher SES
Cordis, Johnson and Johnson, Miami Lakes, Florida) or
he Taxus PES (Boston Scientific, Natick, Massachusetts)
or de novo coronary lesions between July 2003 and De-
ember 2004.
The REAL registry is based on current clinical practice;
herefore, the local hospital ethics committees required only
n ordinary written informed consent to coronary interven-
ion, which was obtained from all patients. The protocol of
he study is in accordance with the Declaration of Helsinki.
rocedures and post-intervention medications. Inter-
entional strategy and device utilization, including drug-
luting stent type, were left to the discretion of the attend-
ng physicians. Periprocedural glycoprotein IIb/IIIa
nhibitors and antithrombotic medications were used ac-
ording to the operator’s decision and current guidelines.
ifelong aspirin was prescribed to all patients. At least
-month ticlopidine (250 mg bid) or clopidogrel treatment
75 mg/day) was recommended to all patients treated with
ES, whereas the same treatment was extended to at least 6
onths for patients treated with PES.
efinitions and follow-up. The primary end point of the
urvey was the occurrence of major adverse cardiac events
MACE), defined as: 1) death (cardiac and non-cardiac);
) non-fatal acute myocardial infarction (MI); and 3) target
essel revascularization (TVR). Myocardial infarction dur-
ng follow-up was diagnosed by local cardiologists at the
ospital of admission according to standard criteria (in-
reased levels of troponin or creatinine kinase-MB fraction
n association with chest pain and/or ischemic electrocar-
iographic changes). Target vessel revascularization was
efined as any re-intervention (surgical or percutaneous) to
reat a luminal stenosis occurring in the same coronary
essel treated at the index procedure, within and beyond the
arget lesion limits. Thrombotic stent occlusion was angio-
raphically documented as a complete occlusion (Throm-
Abbreviations and Acronyms
MACE  major adverse cardiac events
MI  (acute) myocardial infarction
PCI  percutaneous coronary intervention
PES  paclitaxel-eluting stent
REAL  REgistro regionale AngiopLastiche
dell’Emilia-Romagna
SES  sirolimus-eluting stent
TLR  target lesion revascularization
TVR  target vessel revascularizationolysis In Myocardial Infarction flow grade 0 or 1) or a tow-limiting thrombus (Thrombolysis In Myocardial In-
arction flow grade 1 or 2) of a previously successfully
reated artery. In addition, we defined as “possible stent
hrombosis” the occurrence of acute MI in the territory of
he vessel treated and unexplained sudden cardiac death.
esion length and vessel reference diameter were visually
stimated by the operators. Online quantitative coronary
nalysis was allowed if required by the attending physician.
Follow-up was obtained directly and independently from
he Emilia-Romagna Regional Health Agency through the
nalysis of the hospital discharge records and the municipal
ivil registries. All repeat interventions during follow-up
either surgical or percutaneous) were prospectively col-
ected from the single institutions and matched with the
dministrative data to adjust for eventual inconsistency.
ospital records were reviewed for additional information
henever deemed necessary. Specific queries were sent to
he single institution to justify/correct discrepancies be-
ween administrative data, largely provided by independent
ardiologists, and data derived from the web-based PCI
atabase, compiled by the interventional cardiologists.
tatistical analysis. Continuous variables were expressed
s mean  SD and were compared using an unpaired
tudent t test. Categorical variables were expressed as counts
nd percentages and the chi-square test was used for compar-
son. The cumulative incidence of adverse events was estimated
ccording to the Kaplan-Meier method and compared by the
og-rank test. Because of the observed differences in baseline
haracteristics between the treatment groups, a propensity
core analysis was carried out by use of a logistic regression
odel for treatment with SES versus PES.
This analysis included a number of clinical, angiographic,
nd procedural variables, such as age, gender, Charlson
omorbidity index, diabetes mellitus, hypercholesterolemia,
rior angioplasty, prior MI, prior coronary artery bypass
raft, low (35%) left ventricular ejection fraction, diagno-
is at admission (ST-segment elevation MI, unstable
ngina/non–Q-wave MI, stable coronary disease), target
essel, left main stenting, number of lesions treated, refer-
nce vessel diameter, total lesion length, ostial lesion,
hronic total occlusion, and bifurcation.
The logistic model by which the propensity score was
stimated showed good predictive value (C-statistic 
.741) and calibration characteristics by the Hosmer-
emeshow test (p 0.56). The score was then incorporated
nto subsequent proportional-hazards models as a covariate.
ox proportional hazards models were used to assess rela-
ive risk of adverse events in subgroups of patients. There
ere 3 hospitals using only 1 type of stent (2 SES  255
atients; 1 PES  130 cases). Such a strong relationship
etween center and treatment made problematic the inclu-
ion of the variable “center” in the propensity score. How-
ver, to rule out a possible bias, we performed a sensitivity
nalysis excluding the 3 centers using only 1 type of stent
nd adjusting the comparison between SES and PES
hrough a propensity score that included as covariates the
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Sirolimus- Versus Paclitaxel-Eluting Stents October 3, 2006:1312–8ther hospitals. All analyses were performed with the SAS
.2 system (SAS Institute, Cary, North Carolina).
The authors had full access to the data and take respon-
ibility for its integrity. All authors have read and agreed to
he manuscript as written.
ESULTS
n the study period, 2,539 patients enrolled in the registry
eceived at least 1 drug-eluting stent to treat de novo lesions
Table 1. Baseline Clinical Characteristics of Pa
Sirolimus-Eluting Stent (SES) or Paclitaxel-El
Variable
Men, %
Age, yrs  SD
Diabetes mellitus, %
Hypertension, %
Hypercholesterolemia, %
Current smoker, %
Charlson comorbidity index, n  SD
Prior myocardial infarction, %
Prior coronary angioplasty, %
Prior coronary bypass surgery, %
Poor (35%) LVEF, %
Clinical presentation
Stable angina pectoris,* %
Unstable angina pectoris,† %
ST-segment elevation acute myocardial infarction,
Cardiogenic shock, %
*Including silent ischemia; †including non–ST-segment elev
LVEF  left ventricular ejection fraction.
Table 2. Angiographic Lesion Characteristics a
Sirolimus-Eluting Stent (SES) and in the Pacl
Variable SES (n
Treated coronary vessel
Left anterior descending, %
Left circumflex, %
Right, %
Left main, %
Unprotected left main, %
Bypass graft, %
Saphenous vein graft, %
Arterial graft, %
Lesion type
A, %
B1, %
B2, %
C, %
Bifurcation, %
Ostial lesion, %
Chronic total occlusion, %
Lesion length,† mm  SD 20.2
Reference diameter,† mm  SD 2.8
Lesion length 20 mm
Multi-vessel intervention,‡ %
Number of lesions treated, n  SD 1.2
Average stent length, mm  SD 23.7
Average stent diameter, mm  SD 2.8
Total lesion length, mm  SD 24.2
Total stent length,‡ mm  SD 28.1
Complete procedural success,‡ %*Total number of lesions; †visual estimation; ‡referred to 992 patiof which 1,556 received SES and 983 PES). Patients who
eceived both types of stents and patients also treated with
are-metal stents were excluded. Therefore, there were
,676 eligible patients (SES, n  992; PES, n  684) with
,130 lesions (SES, n 1,175; PES, n 955). Baseline and
rocedural characteristics of this population are shown in
ables 1 and 2. Overall, 29% of the patients had diabetes,
3% had prior MI, and 9% had poor left ventricular
unction. ST-segment elevation MI was diagnosed at ad-
s According to Treatment With
Stent (PES)
SES (n  992) PES (n  684) p Value
74 77 0.12
64  11 64  11 0.39
29.3 28.1 0.63
67.6 67.1 0.82
61.2 56.6 0.06
26.8 28.6 0.45
1.1  1.1 0.9  1.1 0.0004
25.6 18.2 0.0007
8.5 9.8 0.43
8.7 10.4 0.30
11.4 6.6 0.004
39.9 43.9 0.11
45.8 46.5 0.78
14.3 9.6 0.004
0.7 0.3 0.26
cute myocardial infarction.
rocedural Details for the Patients in the
-Eluting Stent (PES) Groups
,175)* PES (n  955)* p Value
51.5 0.0001
18.3 0.63
26.0 0.0001
2.4 0.57
2.2 0.76
1.8 0.76
1.4 0.99
0.4 0.57
4.9 0.09
28.6 0.002
45.7 0.01
20.8 0.0001
15.8 0.0008
9.7 0.35
7.5 0.0002
.0 17.6  8.1 0.0001
.3 2.9  0.4 0.0001
26.5 0.0001
22.2 0.0001
.4 1.4  0.7 0.0001
.3 20.5  8.9 .0001
.3 3.0  0.4 .0001
3.3 26.1  15.4 0.02
4.3 28.5  17.3 0.56
99.2 0.75tient
uting
%nd P
itaxel
 1
60.4
19.1
15.5
2.8
2.4
2.0
1.4
0.6
3.4
19.6
39.9
37.1
21.5
11.0
12.8
 9
 0
37.7
11.6
 0
 9
 0
 1
 1
99.1ents in the SES group and 684 patients in the PES group.
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October 3, 2006:1312–8 Sirolimus- Versus Paclitaxel-Eluting Stentsission in 12%, whereas multi-vessel PCI was performed in
6%. Few, though remarkable, differences were observed
etween the two treatment groups. Prior MI and poor left
entricular ejection fraction were more frequently observed
n the SES group, which showed a higher Charlson comor-
idity index as well (Table 1). The SES was also used more
han PES in patients admitted with ST-segment elevation
I (SES 14.3% vs. PES 9.6%; p  0.004) and in the
reatment of the left anterior descending coronary artery
60.4% SES vs. 51.5% PES; p  0.0001), type C lesions
37.1% SES vs. 20.8% PES; p  0.0001), bifurcations
21.5% SES vs. 15.8% PES; p  0.0008), and chronic total
cclusion (12.8% SES vs. 7.5% PES; p  0.0002).
Conversely, the PES was more used to accomplish
ulti-vessel interventions (11.6% SES vs. 22.2% PES; p 
.0001). Accordingly, the average number of lesions treated
1.2  0.4 SES vs. 1.4  0.7 mm PES; p  0.0001) and
otal lesion length were greater in the PES group. However,
n the SES group, individual lesions were longer (18.9 9.3
m SES vs. 16.8  8.2 mm PES; p  0.0001) and
eference vessel diameter smaller (2.8  0.4 mm SES vs.
.9  0.4 mm PES; p  0.0001) than in the PES group.
omplete procedural success was achieved in 99% of the
rocedures in both groups.
Median follow-up was 296 days (range 90 to 639 days).
he 1-year cumulative incidence of death (2.5% SES vs.
.7% PES; p 0.44) and MI (3.8% SES vs. 4.2% PES; p
.77) was similar in the 2 groups (Table 3). However, rates
f TVR (5.0% SES vs. 10.0% PES; p  0.0008) and target
esion revascularization (TLR) (3.4% SES vs. 6.9% PES; p
0.006) were significantly lower in the SES group, as was
he cumulative incidence of MACE (9.2% SES vs. 14.1%
ES; p  0.007). The incidence of angiographic stent
hrombosis was 0.7% in both groups (p  0.6). Possible
tent thrombosis (sudden death or acute MI in the territory
f the same vessel treated) occurred in 0.7% of the SES
roup and 0.8% of the PES group (p  0.46).
Table 3. One-Year Clinical Outcome
SES (n 
Unadjusted
Death, % 2.5
Acute myocardial infarction, % 3.8
Target vessel revascularization, % 5.0
All MACE, % 9.2
Target lesion revascularization, % 3.4
Angiographic stent thrombosis, % 0.7*
Acute/subacute thrombosis, % 0.3†
Possible stent thrombosis, % 0.7‡
Overall stent thrombosis, % 1.3§
Propensity score-adjusted
Death, % 1.9
Acute myocardial infarction, % 3.6
Target vessel revascularization, % 4.7
All MACE, % 8.4
Target lesion revascularization, % 3.1*p  0.65 by log-rank test; †p  0.38 by log-rank test; ‡p  0.47
CI  confidence interval; HR  hazard ratio; MACE  majoropensity score analysis. To adjust for differences in
aseline clinical and angiographic characteristics, a propen-
ity score analysis of the data was carried out as previously
escribed. As shown in Figure 1, this analysis confirmed a
imilar incidence of death and MI between the 2 cohorts,
nd a lower incidence of TVR, TLR, and MACE in the SES
roup. The separate analysis performed after exclusion of the 3
enters using only 1 of the 2 stents gave similar results,
lthough with reduced statistical power (MACE: hazard ratio
HR] 0.61, 95% confidence interval [CI] 0.40 to 0.93, p 
.02; TVR: HR 0.59, 95% CI 0.33 to 1.03, p  0.06).
The impact of SES and PES implantation on the risk of
ubsequent TVR in specific subsets is shown in Figure 2.
irolimus-eluting stents were associated with a similar risk
eduction across many subgroups. Not surprisingly, the
enefit of SES appeared significantly more pronounced in
mall vessels (2.5 mm, HR 0.13, 95% CI 0.03 to 0.68) and
ong lesions (20 mm, HR 0.35, 95% CI 0.17 to 0.73).
onversely, in this study the effect of SES and PES in
iabetic patients was similar (HR 0.97, 95% CI 0.45 to
.10).
ISCUSSION
he major finding of this study is that in a real-world
omplex population, SES is associated with a lower risk of
einterventions compared to the PES. This result deserves
ome attention, because a very intense debate is ongoing
bout the relative performance of these 2 drug-eluting stents
n clinical practice.
In randomized head-to-head comparisons, the SES has
een consistently associated with superior suppression of neo-
ntimal hyperplasia compared to the PES (6–9). However, the
eduction of in-stent and in-segment late loss was not always
aralleled by a reduction of binary restenosis, need for repeat
evascularization, and MACE. In fact, in the SIRTAX
Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for
) SES (n  684) HR 95% CI
2.7 0.87 0.48–1.59
4.2 0.94 0.56–1.56
10.0 0.50 0.34–0.77
14.1 0.66 0.49–0.91
6.9 0.51 0.31–0.83
0.7* — —
0.6† — —
0.8‡ — —
1.6§ — —
3.1 0.52 0.26–1.04
4.5 0.85 0.48–1.51
10.7 0.45 0.29–0.70
15.3 0.56 0.39–0.78
7.4 0.43 0.25–0.74992by log-rank test; §p  0.40 by log-rank test.
r adverse cardiac events.
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Sirolimus- Versus Paclitaxel-Eluting Stents October 3, 2006:1312–8oronary Revascularization) trial the 9-month incidence of
ll MACE, TLR, and TVR was significantly lower in the
ES than in the PES group, whereas in the larger multi-
enter REALITY trial, neither binary restenosis nor
ACE and TVR rates were reduced by the SES as
ompared to the PES (7). Previous studies showed that
mall but clinically important differences in bare-metal stent
erformance might become more obvious as the patients’
ype and lesions treated become more complex (11). This
ypothesis also was postulated for comparison between
igure 1. Propensity score-adjusted cumulative incidence of (A) death and
cute myocardial infarction (AMI), (B) target vessel revascularization
TVR), and (C) major adverse cardiac events (MACE) in the paclitaxel-
luting stent (PES) and in the sirolimus-eluting stent (SES) groups. CI 
onfidence interval.rug-eluting stents (12). Maximal suppression of neointi- tal hyperplasia is likely to be particularly important, for
xample, in small vessels (13), which can accommodate less
issue inside the stent, and in diabetic patients, who exhibit
n exaggerated neointimal proliferative response following
CI (14). Indeed, a clinical advantage of the SES over PES
as observed in those trials focused on complex patients
uch as the ISAR-DESIRE (Intracoronary Stenting and
ngiographic Results—Drug-Eluting Stents for In-Stent
estenosis) (6), a study comparing SES, PES, and balloon
ngioplasty for prevention of recurrences in patients with
oronary in-stent restenosis; and in the SIRTAX trial (8),
hich enrolled a relatively complex group of patients. Thus,
ecause increased patient and lesion complexity is reflected
n everyday “real-world” PCI, this has to be considered the
deal scenario for comparison between competing drug-
luting stents.
In this context, the result of this large, multicenter,
aily-practice registry supporting some clinical advantage of
ES over PES is noteworthy. In other words, the angio-
raphic superiority of SES may have a concrete impact on
linical outcome in the general population. The relationship
etween angiographic late loss and TVR in the drug-eluting
tent era remains a large outstanding question. Whereas late
oss has been shown to be monotonically related to reste-
osis risk even in drug-eluting stent studies (15), coronary
tents result in large lumens with “room” to accommodate
p to approximately 0.5 to 0.65 mm of tissue before the
ikelihood of clinical restenosis increases substantially (16).
ence, both SES and PES are well below this threshold,
hich can justify the similar clinical outcome observed in
ome randomized trials with selective inclusion criteria.
onversely, the 55% risk reduction of TVR observed with
ES compared to PES in our registry indicates that small
ifferences in late lumen loss may become relevant in
omplex patients and lesions. The results of our study are
oncordant with a recent meta-analysis of all head-to-head
andomized trials (17), which showed that patients receiv-
ng SES had a significant lower risk of restenosis and TVR
ompared with those receiving PES.
Conversely, conflicting results emerged from other
egistries. A non-significant trend toward fewer revascu-
arizations in SES-treated patients was observed in the
ESEARCH (Rapamycin-Eluting Stent Evaluated At
otterdam Cardiology Hospital) registry (18), whereas no
ifferences between the two devices were noted in the large
TENT (Strategic Transcatheter Evaluation of New Ther-
pies) registry (C. Simonton, personal communication,
ranscatheter Cardiovascular Therapeutics 2005) and in the
ilan registry (19). However, it should be noted that in the
ESEARCH registry a large proportion of patients treated
ith SES, mainly those with high-risk features (20), under-
ent routine angiography at follow-up (38%), and this was
ot the case for the PES group. Therefore, the negative
mpact of repeat angiography in SES-treated patients might
ave attenuated the difference between the 2 devices. On
he other side, only preliminary 9-month results have been
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October 3, 2006:1312–8 Sirolimus- Versus Paclitaxel-Eluting Stentsresented from the STENT registry, and this follow-up
ay be too short to detect differences in clinical restenosis
ates (21). Finally, data from the Milan registry are impor-
ant because they represent a really complex population, but
note of caution in interpretation of results is mandatory
iven the relatively limited number of patients enrolled
around 500).
Notably, in the REAL registry, the SES was found to be
uperior to the PES in most subgroups analyzed (Fig. 2). As
xpected, the positive effect of SES was more evident in
atients with complex coronary anatomy such as those with
ong lesions and small vessels. Conversely, virtually equal
esults were observed in diabetic patients. With the inherent
imitations of subgroup analyses, this might reflect a similar
linical efficacy of the 2 devices in these patients. Indeed, in
he ISAR-DIABETES trial, SES reduced late loss and
inary restenosis compared to the PES, but the reduction of
linical events was not statistically significant (9). In addi-
ion, diabetic patients are known to have a higher symp-
omatic threshold for angina pectoris, and in the REAL
egistry virtually all reinterventions can be considered
linically driven. Therefore, a number of diabetic patients
ay have developed silent restenosis, thus decreasing the
hance to detect a clinical difference between stents in
his subgroup. Accordingly, in a subgroup analysis of the
ESEARCH registry, clinically driven TVR was not sig-
ificantly reduced by SESs in comparison to bare-metal
tents in diabetic patients, who did not undergo routine
ngiographic follow-up (22).
The REAL registry confirms once again the effectiveness
f both SES and PES in the prevention of restenosis and
ew revascularizations. Indeed, the 1-year incidence of
igure 2. Hazard ratio of 1-year target vessel revascularization (Cox pro
ngiographic characteristics. AMI  actue myocardial infarction; CI  con
rtery; NQWMI  non–Q-wave myocardial infarction; PCI  percutaneVR in the 2 groups was remarkably low (5% to 10%), tespite the complex characteristics of the population en-
olled, substantiating the results of previous studies and
losely resembling the results of the real-world SIRTAX
rial (8).
A possibly different safety profile between the SES and
he PES has been evoked by the REALITY trial. The
nvestigators evaluated the number of acute and subacute
tent thromboses within the first 30 days of the trial,
etecting a 4-fold statistically significant increase in the
umber of stent thromboses in the patients who received the
ES compared with those who received the SES (1.8% vs.
.4%, p  0.0196) (7). In our registry, we did not find a
ignificant difference in the incidence of stent thrombosis
ver 1 year between the 2 stents (both angiographically
ocumented and clinical stent thrombosis, including sudden
eath and acute MI in the same territory of the vessel
reated), confirming previous analyses of data from random-
zed trials (23) and large registries (24). Both drug-eluting
tents have been associated with delayed endothelialization
nd signs of persistent local inflammation, although the
herapeutic window of PES may be somewhat narrower
25). Although a precise analysis of actual antiplatelet
herapy in our registry was not performed, longer dual
ntiplatelet therapy prescribed by design to patients receiv-
ng PES may have contributed to limit and equalize the
ncidence of stent thrombosis.
tudy limitations. This study suffers the obvious limita-
ions of observational non-randomized studies. On the
ther hand, it carries important and complementary infor-
ation derived from a real-world registry, given the inclu-
ion of patients and lesions often excluded from randomized
rials. The exclusion from this analysis of patients also
onal hazards models) in subgroups of patients according to clinical and
ce interval; HR  hazard ratio; LAD  left anterior descending coronary
oronary intervention.portireated with bare-metal stents did not give a precise picture
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EAL registry. However, consistent with this report, in the
ntire REAL population (2,539 patients treated with drug-
luting stents in the same period), SES was used more than
ES in higher risk lesions (longer lesions and smaller
eference diameter); in more compromised patients; and in
atients with acute MI, poor left ventricular function,
hronic total occlusions, or bifurcations. The PES was
referred for left main treatment and multi-vessel interven-
ion. This situation is not surprising, given the different
ody of evidence available for the 2 stents at the time of
nrollment, different sizes of stents available, and the
ifferent market strategies of the 2 producing companies.
emarkably, in this larger population SES implantation was
ssociated with a similar reduction of revascularizations and
ardiac events, both in the unadjusted and in the propensity
core-adjusted analyses (data not shown). Finally, although
ropensity analyses do not completely overcome the pitfalls
f non-randomized comparisons assessing the effectiveness
f health care interventions, they are known to be a valuable
pproach for taking adequately into account the potential
onfounding effect attributable to between-groups imbal-
nces in case mix (26).
onclusions. In this large and complex real-world popu-
ation, the use of SES reduced the 1-year incidence of
dverse cardiac events as compared with PES, mainly by
ecreasing the need for repeat revascularizations.
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